Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax

References

• Rassenti LZ, Balatti V, Ghia EM, et al. MicroRNA dysregulation to identify therapeutic target combinations for chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2017;114(40):10731–10736.
   PubMed Web of Science ®Google Scholar
• Robertson LE, Plunkett W, McConnell K, et al. Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia. 1996;10:456–459.
   PubMed Web of Science ®Google Scholar
• Kipps TJ, Stevenson FK, Wu CJ, et al. Chronic lymphocytic leukaemia. Nat Rev Dis Primers. 2017;3:16096.
   PubMed Web of Science ®Google Scholar
• Al-Katib AM, Sun Y, Goustin AS, et al. SMI of Bcl-2 TW-37 is active across a spectrum of B-cell tumors irrespective of their proliferative and differentiation status. J Hematol Oncol. 2009;2:8.
   PubMed Web of Science ®Google Scholar
• Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202–208.
   PubMed Web of Science ®Google Scholar
• Vogler M, Butterworth M, Majid A, et al. Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood. 2009;113(18):4403–4413.
   PubMed Web of Science ®Google Scholar
• Klanova M, Klener P. BCL-2 proteins in pathogenesis and therapy of B-Cell non-Hodgkin lymphomas. Cancers (Basel). 2020;12(4):938.
   Web of Science ®Google Scholar
• Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225–2236.
   PubMed Web of Science ®Google Scholar
• Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311–322.
   PubMed Web of Science ®Google Scholar
• Anderson MA, Deng J, Seymour JF, et al. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood. 2016;127(25):3215–3224.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17(6):768–778.
   PubMed Web of Science ®Google Scholar
• Seymour JF, Ma S, Brander DM, et al. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol. 2017;18(2):230–240.
   PubMed Web of Science ®Google Scholar
• Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378(12):1107–1120.
   PubMed Web of Science ®Google Scholar
• Kater AP, Seymour JF, Hillmen P, et al. Fixed duration of venetoclax-rituximab in relapsed/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO Phase III Study. J Clin Oncol. 2019;37(4):269–277.
   PubMed Web of Science ®Google Scholar
• Sun Y, Jin K, Clark KR, et al. Adeno-associated virus-mediated delivery of BCL-w gene improves outcome after transient focal cerebral ischemia. Gene Ther. 2003;10(2):115–122.
   PubMed Web of Science ®Google Scholar
• Miyamoto Y, Hosotani R, Wada M, et al. Immunohistochemical analysis of Bcl-2, Bax, Bcl-X, and Mcl-1 expression in pancreatic cancers. Oncology. 1999;56(1):73–82.
   PubMed Web of Science ®Google Scholar
• Lee EF, Harris TJ, Tran S, et al. BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival. Cell Death Dis. 2019;10(5):342.
   PubMedGoogle Scholar
• Ramsey HE, Fischer MA, Lee T, et al. A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia. Cancer Discov. 2018;8(12):1566–1581.
   PubMed Web of Science ®Google Scholar
• Agarwal B, Naresh KN. Bcl-2 family of proteins in indolent B-cell non-Hodgkin's lymphoma: study of 116 cases. Am J Hematol. 2002;70(4):278–282.
   PubMed Web of Science ®Google Scholar
• Cho-Vega JH, Rassidakis GZ, Admirand JH, et al. MCL-1 expression in B-cell non-Hodgkin's lymphomas. Hum Pathol. 2004;35(9):1095–1100.
   PubMed Web of Science ®Google Scholar
• Johnston JB, Paul JT, Neufeld NJ, et al. Role of myeloid cell factor-1 (Mcl-1) in chronic lymphocytic leukemia. Leuk Lymphoma. 2004;45(10):2017–2027.
   PubMed Web of Science ®Google Scholar
• Baliakas P, Jeromin S, Iskas M, ERIC, the European Research Initiative on CLL, et al. Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. Blood. 2019;133(11):1205–1216.
   PubMed Web of Science ®Google Scholar
• Oscier DG, Gardiner AC, Mould SJ, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood. 2002;100(4):1177–1184.
   PubMed Web of Science ®Google Scholar
• Anderson MA, Tam C, Lew TE, et al. Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. Blood. 2017;129(25):3362–3370.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, International Workshop on Chronic Lymphocytic Leukemia, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446–5456.
   PubMed Web of Science ®Google Scholar
• Del Giudice I, Raponi S, Della Starza I, et al. minimal residual disease in chronic lymphocytic leukemia: a new goal? Front Oncol. 2019;9:689.
   PubMed Web of Science ®Google Scholar
• Tessoulin B, Papin A, Gomez-Bougie P, et al. BCL2-family dysregulation in B-cell malignancies: from gene expression regulation to a targeted therapy biomarker. Front Oncol. 2018;8:645.
   PubMed Web of Science ®Google Scholar
• Rassidakis GZ, Jones D, Lai R, et al. BCL-2 family proteins in peripheral T-cell lymphomas: correlation with tumour apoptosis and proliferation. J Pathol. 2003;200(2):240–248.
   PubMed Web of Science ®Google Scholar
• Butterworth M, Pettitt A, Varadarajan S, et al. BH3 profiling and a toolkit of BH3-mimetic drugs predict anti-apoptotic dependence of cancer cells. Br J Cancer. 2016;114(6):638–641.
   PubMed Web of Science ®Google Scholar
• Sanz L, Garcia-Marco JA, Casanova B, et al. Bcl-2 family gene modulation during spontaneous apoptosis of B-chronic lymphocytic leukemia cells. Biochem Biophys Res Commun. 2004;315(3):562–567.
   PubMed Web of Science ®Google Scholar
• Blombery P, Thompson ER, Nguyen T, et al. Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax. Blood. 2020;135(10):773–777.
   PubMed Web of Science ®Google Scholar
• Deeks ED. Venetoclax: first global approval. Drugs. 2016;76(9):979–987.
   PubMed Web of Science ®Google Scholar
• Yosifov DY, Wolf C, Stilgenbauer S, et al. From biology to therapy: the CLL success story. HemaSphere. 2019;3(2):e175.
   PubMed Web of Science ®Google Scholar
• Vogler M. BCL2A1: the underdog in the BCL2 family. Cell Death Differ. 2012;19(1):67–74.
   PubMed Web of Science ®Google Scholar
• Schieber M, Ma S. The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma. Blood Lymphat Cancer. 2019;9:9–17.
   PubMed Web of Science ®Google Scholar
• Adams CM, Clark-Garvey S, Porcu P, et al. Targeting the Bcl-2 family in B cell lymphoma. Front Oncol. 2018;8:636.
   PubMed Web of Science ®Google Scholar
• Adams CM, Mitra R, Gong JZ, et al. Non-Hodgkin and Hodgkin lymphomas select for overexpression of BCLW. Clinical cancer research: an official journal of the American Association for. Clin Cancer Res. 2017;23(22):7119–7129.
   PubMedGoogle Scholar
• Cui J, Placzek WJ. Post-transcriptional regulation of anti-apoptotic BCL2 family members. Int J Mol Sci. 2018;19:308.
   Web of Science ®Google Scholar